Abstract
Aim:
To ascertain if the Patient Enablement Instrument (PEI) could be adapted for use in asthma management, and to use it to evaluate “enablement” in patients with asthma randomised to either a fixed or adjustable medication dosing regime.
Methods:
The original Patient Enablement Instrument was modified by making a minor chc-nge to the opening statement. 228 adults with asthma from 72 UK general practices were recruited to the study. The internal and external consistencies of the modified PEI were assessed. Individual scores were compared across treatment groups.
Results:
The modified PEI had high internal consistency. There was a significant correlation between modified PEI total score and change in Mini Asthma Quality of Life Questionnaire. A significantly greater proportion of patients using adjustable medication dosing had a clinically relevant treatment benefit.
Conclusions:
The Patient Enablement Instrument can be used to measure “enablement” in asthma.
Keywords: Asthma, Validation studies, Enablement, Self management plan
Full Text
The Full Text of this article is available as a PDF (258.0 KB).
Footnotes
John Haughney has received fees from AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme for speaking at meetings, and from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Schering Plough for consulting.
Philip Cotton has spoken at meetings for AstraZeneca but has not received personal fees for doing so.
Jan-Paul Rosen and Ken Morrison are full time employees of AstraZeneca UK Ltd.
David Price has no shares in pharmaceutical companies. He has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: 3M, Altana, AstraZeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering Plough. He has received honoraria for advisory panels from: 3M, Altana, AstraZeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer and Schering Plough. He or his research team have received funding for research projects from: 3M, Altana, AstraZeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering Plough and Viatris.